← Therapy pipeline
Investigational · Obesity development

Oral ribupatide

KAI-9531 · HRS9531 · Ribupatide · Kailera Therapeutics

Once-daily oral ribupatide is in Phase 3 in China. The global Phase 3 program is planned for the first half of 2027.

GLP-1GIP
Obesity stagePhase 3Updated as of November 2026
SponsorKailera Therapeutics
TargetsGLP-1 + GIP
RouteOral tablet
DevelopmentObesity-specific
01 / Evidence

Selected study results

China oral ribupatide Phase 2Mean body-weight changeBody weight decreased 12.1% · 26 weeks · Phase 2
Phase 2 · Oral · Sponsor-reported numerical results

Mean body-weight change · 26 weeks

Study focus: Weight management

Up to 12.1% mean weight loss with oral ribupatide in the 26-week Phase 2 study.

Investigational regimen
12.1%

Adults with obesity in China · 25 mg or 50 mg once daily · N not included in this summary · Efficacy estimand; sponsor-reported conference data. Results & methods ↗

Sponsor summary does not provide the comparator-arm estimate in this update. Vomiting was reported in 11.4% and 7.5% at 25 mg and 50 mg, respectively.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

Tolerability

Safety context

Sponsor-reported vomiting occurred in 11.4% at 25 mg and 7.5% at 50 mg in the China Phase 2 oral study.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

TabletOral tablet · Once daily
Phase 3China Phase 3 recruiting. Global Phase 3 planned for the first half of 2027.
Milestone → next

Latest: China Phase 2 reported up to 12.1% mean weight loss at Week 26. The separate China Phase 3 tablet study started July 24, 2026.

Next: Global Phase 3 obesity trials planned for the first half of 2027.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies1 record

Phase 3

HRS9531 tablets · China Phase 3

Weight management
Study: RecruitingResults: No registry results posted yetStatus reviewed November 2026

Placebo-controlled study of oral HRS9531 in an estimated 675 adults with overweight or obesity. Week-52 primary endpoints are percentage weight change and the proportion achieving at least 5% weight loss.

Phase 2 studies1 record

Phase 2

China oral ribupatide Phase 2

Weight management
Study: CompletedResults: Sponsor results shown aboveStatus reviewed September 2026

Adults with obesity; 25 mg and 50 mg oral doses, 26 weeks.